Why You Can Plateau on Wegovy — and What It Means

The biggest myth: a plateau means Wegovy has stopped working

This is the misconception our prescribers hear most often, and it is worth correcting clearly. A plateau on Wegovy is not the same thing as the medicine ceasing to act. Semaglutide continues to bind GLP-1 receptors, continues to slow gastric emptying, and continues to dampen appetite signals even when the number on the scales has barely shifted for three or four weeks.

What changes is the body's response to being lighter. When you lose a meaningful amount of weight, your resting metabolic rate falls, a smaller body simply needs fewer calories to function. At the same time, hormones involved in hunger and fat storage shift to resist further loss. This is a well-documented physiological defence mechanism, and it operates independently of which weight-loss treatment you are using. Semaglutide blunts appetite considerably, but it cannot fully override the metabolic adaptation that follows significant weight reduction.

The STEP 1 trial, published in the New England Journal of Medicine, showed that the steepest phase of weight loss on 2.4 mg semaglutide occurred in roughly the first 20 weeks. The rate then visibly slowed before stabilising around weeks 60–68. Participants who appeared to plateau mid-trial did not, on average, regain weight while remaining on treatment. The plateau was real; so was the continued effect.

If you are wondering whether a Wegovy plateau is normal for most people, the short answer is yes, it is the rule rather than the exception at some point during treatment.

Why the plateau happens when it does

Timing matters here. The first flat period often falls around the 16–20 week mark, which coincides with being on or approaching the 1.7 mg maintenance dose. A second common stall appears later, typically between months six and twelve, once the body has had time to adapt to the new weight range.

Several things converge to produce a plateau. Lean muscle mass tends to decrease during rapid weight loss, and muscle burns more calories at rest than fat does. Sleep disruption (common when GI side effects like nausea are present early in treatment) can raise ghrelin, the hunger hormone, and undermine the appetite suppression semaglutide provides. Highly processed foods continue to drive reward-based eating even when GLP-1 receptor activity is high, so dietary composition can either deepen or shorten a stall.

There is also a dose dimension. For people who have not yet reached 2.4 mg, the plateau sometimes precedes a dose increase. Titration steps are decided by a prescriber based on your tolerability and progress, not by a fixed calendar, which is why it is worth understanding what a typical Wegovy weight-loss trajectory looks like before interpreting your own results.

For a broader view of the treatment and how it works, the NHS medicines page for semaglutide covers the mechanism and common effects in plain language.

What can actually shift a plateau, and what can't

Practically speaking, a few things are within your control and worth addressing before concluding the medicine is not working for you. Protein intake is the most consistently cited lever: preserving muscle during weight loss keeps metabolic rate higher, which makes the next phase of loss more likely. Many people on GLP-1 treatment eat less overall but let protein slip, eating smaller portions of whatever is convenient. Consciously prioritising protein at each meal (eggs before the school run, chicken or fish at lunch) does not require a special diet plan, just a reorientation of what fills the plate.

Resistance exercise, even modest amounts, has a similar preserving effect on lean mass. Cardiovascular activity burns calories but does not protect muscle in the same way. If your activity has been mostly walking, adding two short strength sessions per week is worth trying before assuming the medicine has plateaued permanently.

Sleep quality, stress and alcohol consumption all affect cortisol and ghrelin in ways that can entrench a stall. These are not small factors, they interact directly with the same hormonal pathways semaglutide targets.

What cannot shift a plateau on its own is simply waiting and hoping. If you have been flat for more than eight to ten weeks and have addressed the lifestyle factors above, it is a reasonable point to speak to your prescriber. They may review your dose, consider whether you have reached your biological ceiling on this medicine, or discuss what happens next. You can explore practical steps when weight loss stalls on Wegovy in more detail, and read about what others do when they hit this point. For broader context on your treatment options, our treatment overview sets out what is currently available.

If you are considering whether Wegovy is still the right choice for you, our Wegovy overview covers the full picture, including how the newer 7.2 mg dose fits in. And if you want to understand what early results typically look like before a plateau sets in, one-month Wegovy results gives a grounded view of the first phase of treatment.

Wegovy is a prescription-only medicine. Any decision to change dose, pause, or switch treatment needs a prescriber's assessment. Check your eligibility and speak to our clinical team to get a clear picture of where you are and what your options are: start your free consultation.